<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kymera Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/kymera-therapeutics-inc</link>
<description>Latest news and press releases for Kymera Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kymera-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358f0e78dffbe2df101781.webp</url>
<title>Kymera Therapeutics Inc</title>
<link>https://6ix.com/company/kymera-therapeutics-inc</link>
</image>
<item>
<title>Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-to-report-first-quarter-2026-financial-results-on-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-to-report-first-quarter-2026-financial-results-on-april-30-2026</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in</description>
</item>
<item>
<title>Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-us-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to-severe-asthma</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-us-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to-severe-asthma</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial</description>
</item>
<item>
<title>Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to</description>
</item>
<item>
<title>Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-presents-kt-621-broaden-data-in-late-breaking-research-session-at-the-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-presents-kt-621-broaden-data-in-late-breaking-research-session-at-the-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b</description>
</item>
<item>
<title>Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-late-breaking-oral-presentation-of-kt-621-phase-1b-data-at-the-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-late-breaking-oral-presentation-of-kt-621-phase-1b-data-at-the-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new</description>
</item>
<item>
<title>Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with</description>
</item>
<item>
<title>Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “New</description>
</item>
<item>
<title>Kymera Therapeutics to Participate in Upcoming February Investor Conferences</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-participate-upcoming-february-investor-conferences-2026-02-04</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-participate-upcoming-february-investor-conferences-2026-02-04</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class</description>
</item>
<item>
<title>Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-first-patient-dosed-breadth-phase-2b-asthma-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-first-patient-dosed-breadth-phase-2b-asthma-clinical</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial</description>
</item>
<item>
<title>Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-outlines-key-2026-objectives-and-strategy-advance-industry</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-outlines-key-2026-objectives-and-strategy-advance-industry</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in</description>
</item>
<item>
<title>Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-present-44th-annual-120000859</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-present-44th-annual-120000859</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...</description>
</item>
<item>
<title>Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-closing-upsized-602-million-public-offering-and-full</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-closing-upsized-602-million-public-offering-and-full</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class</description>
</item>
<item>
<title>Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-us-fda-fast-track-designation-kt-621-first-class-oral</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-us-fda-fast-track-designation-kt-621-first-class-oral</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial</description>
</item>
<item>
<title>Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-pricing-upsized-602-million-public-offering-2025-12-10</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-pricing-upsized-602-million-public-offering-2025-12-10</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class</description>
</item>
<item>
<title>Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-positive-results-broaden-phase-1b-clinical-trial-kt-621</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-positive-results-broaden-phase-1b-clinical-trial-kt-621</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood,</description>
</item>
<item>
<title>Kymera Therapeutics Announces Proposed Public Offering</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-proposed-public-offering-2025-12-08</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-proposed-public-offering-2025-12-08</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class</description>
</item>
<item>
<title>Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announce-kt-621-broaden-phase-1b-atopic-dermatitis-trial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announce-kt-621-broaden-phase-1b-atopic-dermatitis-trial-results</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera</description>
</item>
<item>
<title>Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-first-patient-dosed-broaden2-phase-2b-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-first-patient-dosed-broaden2-phase-2b-atopic-dermatitis</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in</description>
</item>
<item>
<title>Kymera Therapeutics to Participate in Upcoming December Investor Conferences</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-participate-upcoming-december-investor-conferences-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-participate-upcoming-december-investor-conferences-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class</description>
</item>
<item>
<title>Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update</title>
<link>https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/kymera-therapeutics-inc/news/kymera-therapeutics-announces-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025</description>
</item>
</channel>
</rss>